182 related articles for article (PubMed ID: 24731052)
21. [Interleukin 3 (IL-3) in diagnosis and monitoring of non-small-cell lung cancer].
Mroczko B; Szmitkowski M; Czygier M
Przegl Lek; 1999; 56(12):763-6. PubMed ID: 10789186
[TBL] [Abstract][Full Text] [Related]
22. The prognostic values of CA125, CA19.9, NSE, AND SCC for stage I NSCLC are limited.
Ma S; Shen L; Qian N; Chen K
Cancer Biomark; 2011-2012; 10(3-4):155-62. PubMed ID: 22674301
[TBL] [Abstract][Full Text] [Related]
23. Serum angiopoietin-2 as a clinical marker for lung cancer.
Park JH; Park KJ; Kim YS; Sheen SS; Lee KS; Lee HN; Oh YJ; Hwang SC
Chest; 2007 Jul; 132(1):200-6. PubMed ID: 17505039
[TBL] [Abstract][Full Text] [Related]
24. Serum Sialyl Lewis x and cytokeratin 19 fragment as predictive factors for recurrence in patients with stage I non-small cell lung cancer.
Mizuguchi S; Nishiyama N; Iwata T; Nishida T; Izumi N; Tsukioka T; Inoue K; Uenishi T; Wakasa K; Suehiro S
Lung Cancer; 2007 Dec; 58(3):369-75. PubMed ID: 17697728
[TBL] [Abstract][Full Text] [Related]
25. [Expression and diagnosis value of Fascin in non-small cell lung cancer patients].
Liu YG; Gao XD; Yue WT
Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(31):2505-7. PubMed ID: 24300277
[TBL] [Abstract][Full Text] [Related]
26. Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis.
Xu CH; Wang Y; Qian LH; Yu LK; Zhang XW; Wang QB
Clin Respir J; 2017 Nov; 11(6):765-771. PubMed ID: 26605871
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer.
Matsuoka K; Sumitomo S; Nakashima N; Nakajima D; Misaki N
Eur J Cardiothorac Surg; 2007 Sep; 32(3):435-9. PubMed ID: 17611117
[TBL] [Abstract][Full Text] [Related]
28. Serological investigation of the clinical significance of fascin in non-small-cell lung cancer.
Teng Y; Xu S; Yue W; Ma L; Zhang L; Zhao X; Guo Y; Zhang C; Gu M; Wang Y
Lung Cancer; 2013 Nov; 82(2):346-52. PubMed ID: 24070574
[TBL] [Abstract][Full Text] [Related]
29. Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer.
Lin Q; Chen T; Lin Q; Lin G; Lin J; Chen G; Guo L
J Surg Oncol; 2013 Jun; 107(7):767-71. PubMed ID: 23609137
[TBL] [Abstract][Full Text] [Related]
30. Serum vascular endothelial growth factor (VEGF) and bcl-2 levels in advanced stage non-small cell lung cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Cancer Invest; 2006 Oct; 24(6):576-80. PubMed ID: 16982461
[TBL] [Abstract][Full Text] [Related]
31. A novel detection method of non-small cell lung cancer using multiplexed bead-based serum biomarker profiling.
Lee HJ; Kim YT; Park PJ; Shin YS; Kang KN; Kim Y; Kim CW
J Thorac Cardiovasc Surg; 2012 Feb; 143(2):421-7. PubMed ID: 22104668
[TBL] [Abstract][Full Text] [Related]
32. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker.
Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T
Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441
[TBL] [Abstract][Full Text] [Related]
33. Imbalance between vascular endothelial growth factor and endostatin correlates with the prognosis of operable non-small cell lung cancer.
Hu Y; Hu MM; Shi GL; Han Y; Li BL
Eur J Surg Oncol; 2014 Sep; 40(9):1136-42. PubMed ID: 24998915
[TBL] [Abstract][Full Text] [Related]
34. Centromere protein H is a novel prognostic marker for human nonsmall cell lung cancer progression and overall patient survival.
Liao WT; Wang X; Xu LH; Kong QL; Yu CP; Li MZ; Shi L; Zeng MS; Song LB
Cancer; 2009 Apr; 115(7):1507-17. PubMed ID: 19170237
[TBL] [Abstract][Full Text] [Related]
35. The prognostic value of serum epidermal growth factor receptor level in patients with non-small cell lung cancer.
Ciledağ A; Kaya A; Yetkin O; Poyraz B; Savaş I; Numanoğlu N; Savaş H
Tuberk Toraks; 2008; 56(4):390-5. PubMed ID: 19123074
[TBL] [Abstract][Full Text] [Related]
36. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis.
Takahashi H; Kurishima K; Ishikawa H; Kagohashi K; Kawaguchi M; Satoh H
Anticancer Res; 2010 Sep; 30(9):3833-7. PubMed ID: 20944179
[TBL] [Abstract][Full Text] [Related]
37. Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer.
Derin D; Soydinç HO; Guney N; Tas F; Camlica H; Duranyildiz D; Yasasever V; Topuz E
Lung Cancer; 2008 Feb; 59(2):240-5. PubMed ID: 17875341
[TBL] [Abstract][Full Text] [Related]
38. Diagnostic and prognostic value of serum periostin in patients with non-small cell lung cancer.
Xu CH; Wang W; Lin Y; Qian LH; Zhang XW; Wang QB; Yu LK
Oncotarget; 2017 Mar; 8(12):18746-18753. PubMed ID: 27816968
[TBL] [Abstract][Full Text] [Related]
39. Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are strong prognostic factors in operated early stage NSCLC.
Muley T; Fetz TH; Dienemann H; Hoffmann H; Herth FJ; Meister M; Ebert W
Lung Cancer; 2008 Jun; 60(3):408-15. PubMed ID: 18083270
[TBL] [Abstract][Full Text] [Related]
40. The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer.
Han JY; Choi BG; Choi JY; Lee SY; Ju SY
Lung Cancer; 2006 Nov; 54(2):227-34. PubMed ID: 16935391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
